Surfing NASH returns to its regular podcast schedule with a review of the recently concluded Paris NASH meeting. Presenters and KOLs Scott Friedman and Laurent Castera join Jörn Schattenberg, Louise Campbell and Roger Green for a fascinating final conversation which raises new and interesting topics covered at the event.
Surfing NASH returns to its regular podcast schedule with a review of the recently concluded Paris NASH meeting. Presenters and KOLs Scott Friedman and Laurent Castera join Jörn Schattenberg, Louise Campbell and Roger Green for a conversation around the complex challenges in adequately assessing and treating patients.
Surfing NASH returns to its regular podcast schedule with a review of the recently concluded Paris NASH meeting. In this conversation, presenters and KOLs Scott Friedman and Laurent Castera join Jörn Schattenberg, Louise Campbell and Roger Green to ask and answer questions surrounding the task of testing patients for optimized results under different scenarios.
Surfing NASH returns to its regular podcast schedule with a review of the recently concluded Paris NASH meeting. Presenters and KOLs Scott Friedman and Laurent Castera join Jörn Schattenberg, Louise Campbell and Roger Green for a fascinating conversation that dives deeper into emerging questions surrounding the use of NITs in a landscape which features drug approval.
Surfing NASH returns to its regular podcast schedule with a review of the recently concluded Paris NASH meeting. Presenters and KOLs Scott Friedman and Laurent Castera join Jörn Schattenberg, Louise Campbell and Roger Green for a fascinating session that focuses largely on important and emerging questions surrounding the use of NITs in a landscape which features drug approval. This opening conversation highlights the different presentations delivered by the guests followed by discussion around the liver as a regenerative organ and the use and limitations of NITs.
Surfing NASH returns to its regular podcast schedule with a review of the recently concluded Paris NASH meeting. Presenters and KOLs Scott Friedman and Laurent Castera join Jörn Schattenberg, Louise Campbell and Roger Green for an exciting episode that focuses largely on important and emerging questions surrounding the use of NITs in a landscape which features drug approval. Surf on to learn much more from what always pans out to be an incredibly in-depth and insightful event.
Mazen Noureddin discusses his work on a Metabolomics-Advanced Steatohepatitis Fibrosis Score (MASEF) with Jörn Schattenberg, Louise Campbell and Roger Green. This final session considers a few more populations who might benefit from such a test before the panelists field a final question that speculates what MASEF will look like 2 years from today.
Mazen Noureddin discusses his work on a Metabolomics-Advanced Steatohepatitis Fibrosis Score (MASEF) with Jörn Schattenberg, Louise Campbell and Roger Green. This conversation considers applying the test to pediatric populations and the newly classified Met-ALD population (those with MASLD who consume greater amounts of alcohol per week). Additionally, the group considers what’s next for MESAF and how metabolomic tests are becoming commercially available in different countries.
In this conversation, Mazen Noureddin fields questions from Jörn Schattenberg, Louise Campbell and Roger Green around different application settings for the Metabolomics-Advanced Steatohepatitis Fibrosis Score (MASEF). The group discusses pros and cons of different approaches and speculate on challenges such as cost effectiveness and ease of use.
In this conversation, Mazen Noureddin introduces his recent work around serum identification of at-risk MASH and the recent paper he co-authored on the subject. He describes the aims of the study as well as provides a cogent background for why this work came to be and maintains its relevance.
